AD biomarkers, which act as a proxy for amyloid plaques, neurofibrillary tangles and neurodegeneration, can be assessed using biofluid (cerebrospinal fluid (CSF), plasma) and imaging markers (e.g., brain MRI scan or amyloid-, tau- and 18F-fluorodeoxyglucose (FDG)-PET scan of the brain) (Mahaman et al., 2022). The gene discussed is MAPT; the disease is Alzheimer disease.